tbuckley/cabot-search huggingface dataset:
Incidence, distribution and clinical relevance of microbial contamination of preservation solution in deceased kidney transplant recipients: a retrospective cohort study from China
Authors: X. Yu, R. Wang, W. Peng, H. Huang, G. Liu, Q. Yang, J. Zhou, X. Zhang, J.H. Lv, W. Lei, J. Wu, J. Chen
Journal: Clinical Microbiology and Infection (2019)

ObjectivesTo determine whether microbial contamination of preservation solution (PS) in kidney transplantation is associated with donor-derived infections (DDIs).MethodsWe retrospectively analysed data from 1077 deceased kidney transplant recipients of 560 donors. In all, 1002 PS samples were collected for microbiological assessment to establish the incidence and distribution of contamination. Comparisons between patients with contaminated PS and those with sterile PS were performed to assess the impact of microbial contaminations in perfusate on probable donor-derived infections (p-DDIs), and potential risk factors for p-DDIs were examined.ResultsThe contamination rate of PS was 77.8% (402/517). Bacterial species accounted for 85.6% (887/1036) of the total 1036 isolated microorganisms and 26.5% (275/1002) of the recipients' PS were contaminated by ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.). Enterococcus predominated the microbiological pattern. The incidence of infection was significantly higher in patients with microbial contamination than in patients with sterile PS (13.8% (107/776) versus 7.1% (16/226), p 0.006). The prevalence of p-DDIs was significantly higher in patients with ESKAPE contamination than in patients with other bacterial contamination in PS (7.2% (18/251) versus 1.0% (4/405), p 0.000). Univariate analysis indicated that ESKAPE contamination increased the risk of p-DDIs (p 0.001, OR 3.610, 95% CI 1.678–7.764). Multivariate analysis determined ESKAPE contamination as the only independent risk factor associated with p-DDIs (OR 3.418, 95% CI 1.580–7.393).ConclusionsThe high rate of microbial contaminations in PS is unusual and probably due to poor surgical procedures. Patients whose PS are contaminated by ESKAPE pathogens could have a significantly increased risk of p-DDIs at early post-transplantation.
THU0193 Efficacy and safety of bcd-055 (INFLIXIMAB BIOSIMILAR) in rheumatoid arthritis. results of bcd-055–3/lira phase 3 clinical study
Authors: A. Lila, L. Denisov, T. Plaksina, S. Smakotina, E. Kunder, N. Soroka, A. Kastanayan, O. Nesmeyanova, O. Antipova, E. Ilivanova, A. Eremeeva, E. Dokukina, E. Chernyaeva, R. Ivanov
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Equivalent efficacy of BCD-055 and infliximab (INF) innovator has been previously established (the primary endpoint: ACR20 at Wk14)<sup>1</sup>. <h3>Objectives</h3> The impact of BCD-055 and INF innovator on RA activity has been analysed within 14 week study period. DAS28-CRP(,<sup>4</sup> CDAI and SDAI were evaluated. Additionally, safety data has been collected. <h3>Methods</h3> The study was conducted as international multicenter randomised double-blind placebo controlled study. The study enrolled 426 adults with active RA. Patients were randomised into 2 study arms in 2:1 ratio to receive BCD-055 or INF innovator in dose of 3 mg/kg. In the analysed period of the study, patients received the iv infusions on Wk0, Wk2, Wk6, Wk14. <h3>Results</h3> Efficacy: BCD-055 and INF innovator showed similar impact on RA activity: in both groups significant decline of DAS28-CRP(<sup>4</sup> was observed (figure 1). This result corresponds to positive CDAI and SDAI dynamics (table 2). Medians of CDAI/SDAI on screening indicated high RA activity, while on Wk 14 – moderate activity. Analyses of inflammatory markers (ESR and C-reactive protein) revealed pronounced decline in ESR and CRP levels by Wk 2. No further elevation has been observed. Safety: No differences in safety profiles of BCD-055 and INF innovator has been shown. One of the most frequent AEs were arterial hypertension, anaemia, neutropenia and increase of transaminases. Number of patients with binding and neutralising antibodies also did not differ between groups. Babs were detected in 6.83% patients in BCD-055 arm and in 7.81% in INF innovator arm (p=0.888), Nab were observed in 1.61% and 0.78% patients in same arms (p=0.666). <h3>Conclusions</h3> Treatment with BCD-055 and INF innovator leads to significant decline in RA activity and inflammatory markers by Wk14, which corresponds with previous results of ACR20 assessment1. Both drugs are well tolerated with no differences in safety profiles. The frequency of ADA formation is also comparable. <h3>Reference</h3> [1] Denisov L, Gordeev I, Mazurov V, et al. FRI0208 Comparison of efficacy, safety and pharmacokinetics of infliximab biosimilar (BCD-055) and innovator infliximab Ann Rheum Dis2017;76:560–561. <h3>Disclosure of Interest</h3> A. Lila: None declared, L. Denisov: None declared, T. Plaksina: None declared, S. Smakotina: None declared, E. Kunder: None declared, N. Soroka: None declared, A. Kastanayan: None declared, O. Nesmeyanova: None declared, O. Antipova: None declared, E. Ilivanova: None declared, A. Eremeeva Employee of: JSC BIOCAD, E. Dokukina Employee of: JSC BIOCAD, E. Chernyaeva Employee of: JSC BIOCAD, R. Ivanov Employee of: JSC BIOCAD
THU0198 Immunogenicity associated with a transition from adalimumab reference product to abp 501 in patients with rheumatoid arthritis
Authors: E. Krishnan, D. Mytych, N. Zhang, H. Wang, A. Kaliyaperumal
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> In clinical practice, patients treated with an originator product may be transitioned to a biosimilar. Therefore, it is important to ensure that such transition is safe and is not associated with increased immunogenicity. <h3>Objectives</h3> To study the incidence of binding anti-drug antibodies (bADAs) and neutralising anti-drug antibodies (nADAs) after patients with rheumatoid arthritis (RA) are transitioned from adalimumab reference product (RP) to ABP 501, an approved biosimilar for adalimumab. <h3>Methods</h3> We analysed data from the open-label extension (OLE) of a randomised 26 week phase 3 study (NCT 01970475) comparing ABP 501 and adalimumab. In this OLE study (NCT02114931), patients originally randomised to ABP 501 in the parent study continued on ABP 501 while patients originally randomised to adalimumab (RP) were switched to ABP 501 so that all patients received ABP 501. Specifically, we studied the incidence of new ADAs in patients who were ADA negative at the time of entry into the OLE study. The incidence after excluding transiently elevated ADAs was also examined. <h3>Results</h3> The Table summarises the incidence of ADAs. <h3>Conclusions</h3> Transitioning from adalimumab reference product to ABP 501 was not associated with increased immunogenicity over the observational period of 72 weeks. <h3>Disclosure of Interest</h3> E. Krishnan Shareholder of: Amgen Inc., Employee of: Amgen Inc., D. Mytych Shareholder of: Amgen Inc., Employee of: Amgen Inc., N. Zhang Shareholder of: Amgen Inc., Employee of: Amgen Inc., H. Wang Shareholder of: Amgen Inc., Employee of: Amgen Inc., A. Kaliyaperumal Shareholder of: Amgen Inc., Employee of: Amgen Inc.
Manipulating the Microbiome With Fecal Transplantation to Treat Ulcerative Colitis
Authors: Colleen R. Kelly, Ashwin N. Ananthakrishnan
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FRI0662 Calprotectin s100 a8/a9 in a south african rheumatoid arthritis (RA) cohort
Authors: P. Meyer, G. Van Rooyen, R. Anderson, M. Ally, L. Winchow, N. Govind, M. Tickly, H. Bang
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background:</h3> Calprotectins(CLP) S100 A8/A9 are small calcium binding proteins[1] belonging to the group of damage-associated molecular patterns (DAMPs) or alarmins. They play a key role in the inflammatory response in RA. [2, 3]The measurement of CLP S100 A8/A9 in serum may be a useful strategy to optimize management of patients with RA.[4] <h3>Objectives:</h3> To evaluate serum calprotectin S100 protein (A8 and A8/A9) levels in a South African RA Cohort in relation to disease severity at presentation in comparison with traditional RA-associated autoantibodies. <h3>Methods:</h3> This was an observational, single-centre study, involving patients attending the Rheumatology Clinic of the Department of Internal Medicine, Chris Hani Baragwanath Academic Hospital (CHBAH) and University of the Witwatersrand, South Africa. The cohort consisted of 128 ethnic black RA DMARD-naïve patients. The study was approved by the local ethics committee and patients gave informed consent to participate. <h3>Results:</h3> The baseline demographics and clinical data of the cohort are summarized in table 1. Calprotectin S100 A8 demonstrated a statistically significant association with disease severity[(both SDAI (p=0.005) and DAS 28 (p=0.016)] by linear regression analysis. Calprotectin S100A8/A9 also showed significant associations with SDAI (p=0.010) and DAS28 (p=0.022) figure 1. <h3>Conclusions:</h3> Unlike those of traditional autoantibodies, serum levels of calprotectin correlate strongly with disease severity of RA patients. These findings suggest that calprotectin S100 is a promising biomarker for assessment and monitoring of disease activity in <b>RA.</b> <h3>References</h3> 1. Cesaro A, Anceriz N, Plante A, Page N, Tardif MR, Tessier PA. An inflammation loop orchestrated by S100A9 and calprotectin is critical for development of arthritis. PLoS ONE2012;7(9):e45478. 2. Geven EJ, Van Den Bosch MH, Di Ceglie I, Ascone G, Abdollahi-Roodsaz S, Sloetjes AW, et al. S100A8/A9, a potent serum and molecular imaging biomarker for synovial inflammation and joint destruction in seronegative experimental arthritis. Arthritis Res Ther2016;18(1):247. 3. Nielsen UB, Bruhn LV, Ellingsen T, Stengaard-Pedersen K, Hornung N. Calprotectin in patients with chronic rheumatoid arthritis correlates with disease activity and responsiveness to methotrexate. Scand J Clin Lab Invest2017. doi:10.1080/00365513.2017.1413591:1-6 4. Obry A, Lequerre T, Hardouin J, Boyer O, Fardellone P, Philippe P, et al. Identification of S100A9 as biomarker of responsiveness to the methotrexate/etanercept combination in rheumatoid arthritis using a proteomic approach. PLoS ONE2014;9(12):e115800. <h3>Disclosure of Interest:</h3> None declared
AB0541 Hepcidin and interferon-Α in systemic lupus erythematosus patients
Authors: D. Archimandriti, A.T. Tzallas, T.-E. Memi, P. Spyrou, A.A. Drosos, P.V. Voulgari
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is a chronic autoimmune disease where interferon (IFN) α, is considered to play a central role in its pathogenesis Anaemia of chronic disease (ACD) in SLE is common. Hepcidin may contribute to anaemia by limiting iron availability for erythropoiesis. <h3>Objectives</h3> The aim of the study was to evaluate INF-α and hepcidin levels in sera of anaemic and non-anaemic SLE patients. <h3>Methods</h3> This was a pilot study of SLE patients with established disease. Patients were divided as anaemic and non- anaemic according to the haemoglobin (Hb) levels: Hb value &lt;13.5 gm% for men and &lt;11.5 gm% for females. ACD was defined according the levels of iron and ferritin. Serum hepcidin (the active 25 amino acid form) was measured using ELISA (Peninsula Laboratories International). IFN alpha was also measured using ELISA (eBioscience, affymetric). The inter-assay coefficient of variation was &lt;20% for both assays). All analyses were performed with IBMSPSS Statistics for Windows (version 21). Data are expressed as the mean ±standard deviation (SD). Statistical analysis was performed using Student's t-test for independent samples. The relationships between hepcidin level and all variables were analysed using two-tailed Pearson's correlation test. P values less than 0.05 were considered significant. <h3>Results</h3> Forty SLE patients (36 women and 4 men) were studied. Demographic parameters were as follows: age 46.78±16.04 years, disease duration 10.55±6.58 years. Levels of Hb were 12.49±1.28 g/dl. Levels of INF-α were 0.16±0.47 pgr/ml while hepcidin levels were 2.54±2.63 ngr/ml. When the patients were divided into anaemic (20 patients) and non-anaemic (20 patients) groups<b> (</b>Hb:11.41±0.56 vs. 13.57±0.77 g/dl, p<i>&lt;0.001</i>), patients with anaemia had lower disease duration (9.75±6.16 vs. 11.35±7.03 years, p<i>=0.45</i>), lower levels of INF-α (0.13±0.035 vs. 0.19±0.036 pgr/ml p<i>&lt;0.001</i>) and higher hepcidin levels (2.92±2.9 vs. 2.17±2.35 ngr/ml, p=0.37) than the patients without anaemia. No correlation was observed between levels of hepcidin with all variables. There was also no correlation between hepcidin and INF-α levels. <h3>Conclusions</h3> INF-α does not seem to contribute in ACD pathogenesis in SLE patients and does not correlate with hepcidin levels in SLE patients. Further studies will clarify the role of INF-α in anaemia in SLE. <h3>Disclosure of Interest</h3> None declared
AB1128 Evaluation of serum versican levels in patients with familial mediterranean fever (FMF)
Authors: M.E. Derin, I. Karadağ, A.C. Urhan, G. Toksoylu, G. Asan, M. Bayram, H.O. Doğan, M. Şahin, A. Şahin
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Familial Mediterranean fever (FMF) is an autoinflammatory disease which has self-limiting inflammatory attacks placing in polyserositis.<sup>1</sup> Versican is an extracellular proteoglycan which interacts with receptors that regulate immune system.<sup>2</sup> <h3>Objectives</h3> The aim of this study is to measure serum versican levels between FMF and control group. <h3>Methods</h3> Between June 2017 – ,<sup>Semptember 2017</sup> thirty-seven FMF patients with attack-free period that following-up at Cumhuriyet University Faculty of Medicine Department of Internal Medicine Rheumatology and thirty-five healthy volunteers without any rheumatic, systemic and metabolic diseases were enrolled in this study. Clinical findings of all patients were recorded. Blood tests were examined by Elisa method in Cumhuriyet University Department of Biochemistry. <h3>Results</h3> The median age of the FMF patients was 33(<sup>19–64</sup> years. Of the FMF patients, twenty-one (56.8%) were female and sixteen (43.2%) were male. The median age of control group was 26<sup>18–38</sup> years. Of the control group fourteen (40%) were female and twenty-one (60%) were male. The median versican level was measured as 18.3 ng/ml in FMF group and 23 ng/ml in healthy group (p&lt;0.05). There was no correlation between eritrosit sedimantation rate (ESR), CRP, fibrinogen, serum amyloid-A (SAA) protein other clinical manifestations, medications and versican levels (table 1). <h3>Conclusions</h3> Serum versican level was statistically significant lower in FMF group than in control. On the other hand, there was no statistically significant correlation between versican levels and other parameters in FMF patients with attack-free period. Clinical trials including FMF patients with attack-period, attack-free period and amyloidosis would be designed in order to investigate the possible role of versican. <h3>References</h3> [1] Sahin A, Karakus S, Durmaz Y, Yıldız C, Aydın H, Cengiz AK, Güler D. Evaluation of Ovarian Reserve with Anti-Müllerian Hormone in Familial Mediterranean Fever. Int J Rheumatol2015;2015:380354. doi: 10.1155/2015/380354. Epub 2015 May 12. [2] Frey H, Schroeder N, Manon-Jensen T, Iozzo RV, Schaefer L. Biological interplay between proteoglycans and their innate immune receptors in inflammation. FEBS J. 2013May;280(10):2165–79. doi: 10.1111/febs.12145. Epub 2013 Feb 21. <h3>Disclosure of Interest</h3> None declared
Visit-to-Visit Glycemic Variability and Risks of Cardiovascular Events and All-Cause Mortality: The ALLHAT Study
Authors: Justin B. Echouffo-Tcheugui, Songzhu Zhao, Guy Brock, Roland A. Matsouaka, David Kline, Joshua J. Joseph
Journal: Diabetes Care (2019)

OBJECTIVE The prognostic value of long-term glycemic variability is incompletely understood. We evaluated the influence of visit-to-visit variability (VVV) of fasting blood glucose (FBG) on incident cardiovascular disease (CVD) and mortality. RESEARCH DESIGN AND METHODS We conducted a prospective cohort analysis including 4,982 participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) who attended the baseline, 24-month, and 48-month visits. VVV of FBG was defined as the SD or variability independent of the mean (VIM) across FBG measurements obtained at the three visits. Participants free of CVD during the first 48 months of the study were followed for incident CVD (coronary heart disease [CHD], stroke, and heart failure [HF]) and all-cause mortality. RESULTS Over a median follow-up of 5 years, there were 305 CVD events (189 CHD, 45 stroke, and 81 HF) and 154 deaths. The adjusted hazard ratio (HR) comparing participants in the highest versus lowest quartile of SD of FBG (≥26.4 vs. &amp;lt;5.5 mg/dL) was 1.43 (95% CI 0.93–2.19) for CVD and 2.22 (95% CI 1.22–4.04) for all-cause mortality. HR for VIM was 1.17 (95% CI 0.84–1.62) for CVD and 1.89 (95% CI 1.21–2.93) for all-cause mortality. Among individuals without diabetes, the highest quartile of SD of FBG (HR 2.67 [95% CI 0.14–6.25]) or VIM (HR 2.50 [95% CI 1.40–4.46]) conferred a higher risk of death. CONCLUSIONS Greater VVV of FBG is associated with increased mortality risk. Our data highlight the importance of achieving normal and consistent glycemic levels for improving clinical outcomes.
Prognostic Value of Radiomics Signature By Diagnostic 18F-FDG PET/CT Analysis in Aggressive Non-Hodgkin's Lymphoma
Authors: Blanca Ferrer Lores, Irene Mayorga-Ruiz, Angel Alberich Bayarri, Daniella Morello-González, Irene Pastor-Galán, Blanca Navarro-Cubells, Alicia Serrano, Ana Isabel Teruel, Rosa Dosdá-Muñoz, Carlos Solano, Luis Marti-Bonmati, Maria Jose Terol
Journal: Blood (2018)
NHS pays £1.1m compensation to Jimmy Savile’s victims
Authors: Clare Dyer
Journal: BMJ (2019)

Abuse by the prolific sex offender Jimmy Savile on NHS premises has cost the health service £1.1m (€1.2m; $1.4m) in compensation and legal fees, after his estate contributed just over £53 000 towards these claims.

About £600 000 of the NHS’s contribution went on legal fees, and the remaining £500 000 was paid in damages to 52 victims, showed figures up to 31 October 2018 released under freedom of information laws.

Savile, a DJ and television presenter for the BBC who raised millions of pounds for charity, abused scores of victims over a 50 year period, but his crimes came to light only after his death at age 84 in …
Residual Abdominal Lymphadenopathy after Intensive Frontline Chemoimmunotherapy Is Associated with Inferior Outcome Regardless of MRD Status in Advanced Chronic Lymphocytic Leukemia (CLL)
Authors: Moritz Fürstenau, Jasmin Bahlo, Anna-Maria Fink, Elisabeth Lange, Peter Dreger, Martin Dreyling, Georg Hess, Matthias Ritgen, Michael Kneba, Hartmut Döhner, Stephan Stilgenbauer, Clemens-Martin Wendtner, Valentin Goede, Kirsten Fischer, Sebastian Böttcher, Michael Hallek, Barbara Eichhorst
Journal: Blood (2018)
AB1371 Clinical significance of kl-6 and sp-d as serum markers for interstitial lung disease in patients with connective tissue disease
Authors: K.-E. Lee, J.-H. Kang, D.-J. Park, S.-S. Lee
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> To evaluate the association between serum levels of Krebs von den Lungen-6 (KL-6) and surfactant protein-D (SP-D) and the clinical manifestations and severity of interstitial lung disease (ILD) in patients with connective tissue disease (CTD). <h3>Methods</h3> Eighty patients with various CTDs were included, as follows: 33 with rheumatoid arthritis (RA), 19 with systemic lupus erythematosus (SLE), 10 with systemic sclerosis (SSc), 9 with Sjogren's syndrome (SS), and 9 with inflammatory myositis. KL-6 and SP-D levels were measured using an enzyme-linked immunosorbent assay and defined as abnormal if KL-6 ≥500 U/mL and SP-D ≥110 mg/mL. All patients were simultaneously evaluated for parameters related to disease activity using laboratory tests and a pulmonary function test, and interstitial lung abnormalities (ILA) using chest computed tomography (CT). Patients were subclassified according to ILA score: 0 for no ILD, 1 for indeterminate ILD, 2 for mild ILD, and 3 for advanced ILD based on chest CT scans. <h3>Results</h3> In all, 29 patients had radiologically advanced ILD, 18 had mild ILD, 18 had indeterminate ILD, and 15 had no ILD. A higher ILA score was associated with more severe dyspnea, and decreased volume and percent of functional vital capacity, forced expiratory volume in 1 s, and diffusion capacity of carbon monoxide. As clinical manifestations, a higher ILA score was associated with a higher GAP index but not with the parameters of disease activity. A higher ILA score was associated with higher levels of KL-6 and SP-D and a higher percentage of subjects with abnormal levels, and this was more pronounced in SLE, SSc, and SS than in RA. <h3>Conclusions</h3> Serum levels of KL-6 and SP-D are associated with the radiological severity of ILD. Hence, these can serve as markers for ILD severity, especially in SLE, SSc, and SS. <h3>Disclosure of Interest</h3> None declared